Overview

• The Trump administration's probes into pharmaceutical imports and potential tariffs have created widespread uncertainty for the industry, with no clarity on timing or rates.
• Roche is in direct talks with the U.S. government, seeking tariff exemptions by arguing that its U.S. exports offset its imports.
• To counter potential disruptions, Roche has begun shifting production within its global network and building up inventories in the U.S. and China.
• Roche has announced a $50 billion U.S. investment over five years, creating over 12,000 jobs, as part of broader industry efforts to bolster domestic manufacturing.
• Drugmakers warn that sector-wide tariffs could inflate costs, disrupt supply chains, hinder innovation, and restrict patient access, as they lobby for exemptions and implement mitigation strategies.